Cystamine attenuates lupus-associated apoptosis of ventricular tissue by suppressing both intrinsic and extrinsic pathways

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 9, 2012, Pages 2104-2111

  Tzang, Bor Show ^a,b   Hsu, Tsai Ching ^a,b   Kuo, Cheng Yi ^c   Chen, Tzy Yen ^a,b   Chiang, Szu Yi ^d   Li, Sin Lun ^a   Kao, Shao Hsuan ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c Seeing BioScience Co Ltd   (Taiwan)

^d CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

Apoptosis; Cystamine; Fas; Lupus prone mice; Ventricular tissue

Indexed keywords

APAF1 PROTEIN, MOUSE; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BAD PROTEIN, MOUSE; BCL2 PROTEIN, MOUSE; CASP3 PROTEIN, MOUSE; CASP8 PROTEIN, MOUSE; CASP9 PROTEIN, MOUSE; CASPASE 3; CASPASE 8; CASPASE 9; CYSTAMINE; CYTOCHROME C; FAS ANTIGEN; FAS PROTEIN, MOUSE; ONCOPROTEIN; PROTEIN BAD; PROTEIN BID;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; DRUG EFFECT; HEART VENTRICLE; IMMUNOBLOTTING; MALE; METABOLISM; METHODOLOGY; MOUSE; NEW ZEALAND BLACK MOUSE; NICK END LABELING; PATHOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; BCL-ASSOCIATED DEATH PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; CYSTAMINE; CYTOCHROMES C; HEART VENTRICLES; IMMUNOBLOTTING; IN SITU NICK-END LABELING; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED NZB; PROTO-ONCOGENE PROTEINS;

EID: 84865424904     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01511.x     Document Type: Article

References (30)

1. Ruiz-Irastorza G, Khamashta MA, Castellino G, et al. Systemic lupus erythematosus. Lancet. 2001; 357: 1027-32.
2. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997; 145: 408-15.
3. Manzi S, Wasko MC. Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis. 2000; 59: 321-5.
4. Petri M, Perez-Gutthann S, Spence D, et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992; 93: 513-9.
5. Bjornadal L, Yin L, Granath F, et al. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol. 2004; 31: 713-9.
6. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001; 44: 2331-7.
7. Che J, Li G, Wang W, et al. Serum autoantibodies against human oxidized low-density lipoproteins are inversely associated with severity of coronary stenotic lesions calculated by Gensini score. Cardiol J. 2011; 18: 364-70.
8. Lee HC, Huang KT, Wang XL, et al. Autoantibodies and cardiac arrhythmias. Heart Rhythm. 2011; 8: 1788-95.
9. Laczik R, Szodoray P, Veres K, et al. Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome. Lupus. 2011; 20: 730-5.
10. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999; 42: 1309-11.
11. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun. 2000; 15: 145-51.
12. Jahns R, Boivin V, Schwarzbach V, et al. Pathological autoantibodies in cardiomyopathy. Autoimmunity. 2008; 41: 454-61.
13. Zhao P, Sharma AC, Ren J. Pathogenesis and therapy of autoimmunity-induced dilated cardiomyopathy. Front Biosci. 2009; 14: 1708-15.
14. Chu F, Koomen JM, Kobayashi R, et al. Identification of an inactivating cysteine switch in protein kinase Cepsilon, a rational target for the design of protein kinase Cepsilon-inhibitory cancer therapeutics. Cancer Res. 2005; 65: 10478-85.
15. Seelig GF, Meister A. Gamma-glutamylcysteine synthetase. Interactions of an essential sulfhydryl group. J Biol Chem. 1984; 259: 3534-8.
16. O'Brian CA, Chu F. Post-translational disulfide modifications in cell signaling - role of inter-protein, intra-protein, S-glutathionyl, and S-cysteaminyl disulfide modifications in signal transmission. Free Radic Res. 2005; 39: 471-80.
17. Hsu TC, Chiang SY, Huang CY, et al. Beneficial effects of treatment with transglutaminase inhibitor cystamine on macrophage response in NZB/W F1 mice. Exp Biol Med. 2007; 232: 195-203.
18. Karpuj MV, Becher MW, Springer JE, et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med. 2002; 8: 143-9.
19. Denman AM, Denman EJ, Holborow EJ. Suppression of Coombs-positive haemolytic anaemia in NZB mice by antilymphocyte globulin. Lancet. 1967; 1: 1084-6.
20. Holborow EJ, Denman AM. Autoimmune disease in inbred mice. Clin Exp Immunol. 1967; 2 Suppl: 761-7.
21. Broker LE, Kruyt FA, Giaccone G. Cell death independent of caspases: a review. Clin Cancer Res. 2005; 11: 3155-62.
22. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998; 281: 1312-6.
23. Wolf BB, Green DR. Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem. 1999; 274: 20049-52.
24. Cohen GM. Caspases: the executioners of apoptosis. Biochem J. 1997; 326: 1-16.
25. Ishiyama S, Hiroe M, Nishikawa T, et al. The Fas/Fas ligand system is involved in the pathogenesis of autoimmune myocarditis in rats. J Immunol. 1998; 161: 4695-701.
26. Huang CY, Hsu TC, Kuo WW, et al. Beneficial effects of taurine on cardiac abnormality in NZB/W F1 mice fed with a high-cholesterol diet. J Agric Food Chem. 2009; 57: 8635-42.
27. Kelekar A, Thompson CB. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol. 1998; 8: 324-30.
28. Yang E, Zha J, Jockel J, et al. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell. 1995; 80: 285-91.
29. Li H, Zhu H, Xu CJ, et al. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998; 94: 491-501.
30. Wei MC, Lindsten T, Mootha VK, et al. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 2000; 14: 2060-71.